search
Back to results

Impact of Whey and Leucine on Glycaemia in Adults Without Diabetes (Whey2Glo)

Primary Purpose

Pre Diabetes

Status
Unknown status
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
Whey Protein Isolate
Wheat Protein
Wheat Protein with Leucine
Sponsored by
University of Reading
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Pre Diabetes focused on measuring HbA1c, whey, postprandial glycaemia, cardiometabolic, vascular, leucine, branched chain amino acids (BCAA), glucose control, Milk protein

Eligibility Criteria

20 Years - 70 Years (Adult, Older Adult)All SexesAccepts Healthy Volunteers

Inclusion Criteria:

  • BMI 20-35 kg/m2
  • HbA1c (5.7 - 6.5%) or (38.8 - 47.5 mmol/mol)
  • Fasting glucose 5.5-6.9 mmol/l
  • Fasting total cholesterol <7.5mmol/l
  • Fasting triacylglycerol <4.0 mmol/l
  • Not having a milk, gluten or wheat allergy or lactose intolerability
  • Not having diabetes (HbA1c < 47 mmol/mol) or < 6.5%
  • Not suffering from cardiovascular, renal, gastrointestinal, respiratory, endocrine or liver disease
  • Not having hypertension
  • Not diagnosed with cancer
  • Not having surgery in the previous 6 months
  • Not consuming more than the recommended intake of alcohol (>14 unit/wk)
  • Not being a blood donor 3 months prior to or during the study.
  • Not taking extra protein powder supplements in the previous 2 months
  • Not anaemic (Haemoglobin ≥115 g/l for women and ≥ 130 g/l for men)
  • Not taking medication for raised blood lipids, high blood pressure or for inflammatory conditions.

Exclusion Criteria:

• Females who are breast-feeding, may be pregnant, or if of child-bearing potential and are not using effective contraceptive precautions

Sites / Locations

  • Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Experimental

Arm Label

Whey Protein Isolate

Wheat Protein

Wheat protein with leucine

Arm Description

Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks

Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks

Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks

Outcomes

Primary Outcome Measures

Change in fasting and day long glucose levels
Blood glucose levels will be measured using a clinical chemistry analyser
Change in fasting and day long insulin levels
Blood insulin levels will be measured using ELISA

Secondary Outcome Measures

Change in vascular reactivity measured by Laser Doppler Imaging with iontophoresis
Fasting and day long measurement of vascular reactivity in the microcirculation.
Change in the total and HDL-cholesterol
Fasting total cholesterol and HDL-C will be measured using a clinical chemistry analyser. LDL-C will be calculated using the Friedewald formula
Change in fructosamine
Fructosamine will be measured using a clinical chemistry analyser
Change in C-reactive protein
C-reactive protein
Change in pulse wave analysis
Pulse wave analysis will be measured using the Mobil-O-Graph device
Change in blood pressure
Systolic blood pressure, diastolic blood pressure and pulse pressure
Change in cellular adhesion molecule
VCAM and ICAM will be measured by Luminex, ICAM, P-selectin and E-selectin
Change in selectins
P-selectin and E-selectin will be measured using Luminex
Change in beta-hydroxy butyrate
Beta-hydroxy butyrate will be measured using a clinical chemistry analyser as a marker of ketone bodies
Change in insulin sensitivity
Glucose and insulin levels will be used to estimate insulin sensitivity using the Homeostatic model assessment calculation
Change in non-esterified fatty acids
Non-esterified fatty acids will be measured using a clinical chemistry analyser
Measurement of height
Height will be measured using a stadiometer
Change in body weight
Body weight will be measured using the Tanita scale
Change in body mass index
Body mass index will be calculated from body weight and height measurement
Change in body composition
Body composition will be measured using bioelectrical impedance.

Full Information

First Posted
December 14, 2018
Last Updated
December 20, 2018
Sponsor
University of Reading
Collaborators
Barnham Benevolent Foundation, Jason and Daphne Mermikides Charitable Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT03785951
Brief Title
Impact of Whey and Leucine on Glycaemia in Adults Without Diabetes
Acronym
Whey2Glo
Official Title
Impact of Whey and Leucine on Glycaemia in Adults Without Diabetes But With Moderately Raised HbA1c
Study Type
Interventional

2. Study Status

Record Verification Date
December 2018
Overall Recruitment Status
Unknown status
Study Start Date
December 2018 (Anticipated)
Primary Completion Date
July 2020 (Anticipated)
Study Completion Date
December 2020 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of Reading
Collaborators
Barnham Benevolent Foundation, Jason and Daphne Mermikides Charitable Trust

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
Higher than average blood sugar (glucose) levels are linked to an increased risk of developing type 2 diabetes. As such, there is interest in identifying dietary factors that could lower blood glucose to help reduce the number of people with this disease. Findings from some human studies indicate that dairy products, especially a milk protein (whey), may help the control of blood glucose levels. However, there is a need for further studies to confirm these findings in individuals without diabetes but with higher than average blood glucose levels.
Detailed Description
In the UK, more than 700 people are diagnosed with type 2 diabetes each day. Higher than average (raised) fasting blood sugar (glucose) is a characteristic of those at risk of developing this disease and as a result there is significant interest in dietary factors that could reduce levels of blood glucose, lowering the frequency of type 2 diabetes in the population. Existing scientific evidence suggests an important role of dairy products and especially of whey protein in the control of blood glucose levels. However, there is a need for further studies to confirm these findings in individuals without diabetes but with higher than average blood glucose levels. Milk contains high quality proteins, of which 80% are caseins and 20% are whey proteins. Whey proteins are a rich source of branched-chain amino acids (such as leucine) which are thought to play an important role in regulating blood glucose control and other aspects of cardiovascular disease development in both healthy and type 2 diabetic subjects. However, very few studies in non-diabetic subjects with moderately raised HbA1c, characteristic of long-term poor glucose control, have been performed to investigate how whey protein affects blood glucose levels in the body especially when consumed over the longer term in the daily diet. Furthermore, data are limited on whether the leucine content of protein plays an important role in controlling blood glucose levels. Study aims The main aims of this study is to investigate in adults without diabetes but with moderately raised HbA1c (a long- term marker of blood glucose control) whether a protein obtained from milk and dairy products (whey) has a beneficial effect on fasting and day-long blood glucose and insulin levels compared with a plant based protein (such as wheat). The researchers will also determine if leucine, a particular amino acid (building blocks of protein) found in higher levels in whey protein plays an important role in controlling blood glucose levels. A secondary aim will determine whether the protein interventions influence risk markers for developing heart disease and diabetes including the level of blood lipids, hormones regulating blood sugar levels and blood vessel health. This study will test the hypothesis that the incorporation of whey protein (total protein dose 50 g/d) in the habitual diet for 8 weeks will result in an improvement in fasting and day-long blood glucose and insulin levels, and other risk markers of heart disease and diabetes compared with wheat protein (total protein dose 50 g/d), and that the addition of leucine to wheat (to match the content found in whey protein) will improve blood glucose control. Study design This study will be a long term, double-blind, randomised, controlled, three-way, cross-over study, in which the participants will receive the protein supplements (in random order) for 8 weeks each, with a 4 week wash-out period between the different protein treatments. At the beginning and end of each protein intervention, a fasting blood sample will be collected to determine the longer term effects of the assigned protein supplement on fasting glycaemic control, insulin sensitivity, endothelial function and other cardio-metabolic risk markers, as well as non-invasive measures of blood vessel health. At the beginning of each intervention period, a subset of participants will also undergo a day-long test meal investigation to determine the short-term (postprandial) effects of the protein interventions on the study outcome measures in response to standard sequential test meals containing the assigned protein interventions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Pre Diabetes
Keywords
HbA1c, whey, postprandial glycaemia, cardiometabolic, vascular, leucine, branched chain amino acids (BCAA), glucose control, Milk protein

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Crossover Assignment
Model Description
Double-blind, randomised, controlled, 3-way, cross-over study
Masking
ParticipantInvestigatorOutcomes Assessor
Masking Description
Coded protein products will be used.
Allocation
Randomized
Enrollment
40 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Whey Protein Isolate
Arm Type
Experimental
Arm Description
Subjects are asked to supplement their habitual diet with 56 g of whey protein isolate a day for 8 weeks
Arm Title
Wheat Protein
Arm Type
Experimental
Arm Description
Subjects are asked to supplement their habitual diet with 56 g of wheat protein a day for 8 weeks
Arm Title
Wheat protein with leucine
Arm Type
Experimental
Arm Description
Subjects are asked to supplement their habitual diet with 56 g of wheat protein with leucine a day for 8 weeks
Intervention Type
Dietary Supplement
Intervention Name(s)
Whey Protein Isolate
Intervention Description
Whey protein product isolated from whole milk. 79% Protein with minimal carbohydrate and fat. 50 grams of total supplemental protein/amino acids from whey protein powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.
Intervention Type
Dietary Supplement
Intervention Name(s)
Wheat Protein
Intervention Description
Enzymatically hydrolysed wheat protein containing wheat peptides. 75% Protein with minimal carbohydrate and fat. 50 grams of total supplemental protein/amino acids from whet protein peptide powder consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks in the form of a nutritional shake.
Intervention Type
Dietary Supplement
Intervention Name(s)
Wheat Protein with Leucine
Intervention Description
Enzymatically hydrolysed wheat protein containing wheat peptides with and additional 1.4g of L-leucine. 75% Protein with minimal carbohydrate and fat and a L-leucine concentration equal to whey protein isolate. 50 grams of total supplemental protein/amino acids from wheat protein peptide powder, with added leucine to equal the total content of the whey protein condition, consumed in two 25g (total protein/amino acids) nutrition shakes twice per day for 8 weeks.
Primary Outcome Measure Information:
Title
Change in fasting and day long glucose levels
Description
Blood glucose levels will be measured using a clinical chemistry analyser
Time Frame
Before and after each 8 week intervention.
Title
Change in fasting and day long insulin levels
Description
Blood insulin levels will be measured using ELISA
Time Frame
Before and after each 8 week intervention.
Secondary Outcome Measure Information:
Title
Change in vascular reactivity measured by Laser Doppler Imaging with iontophoresis
Description
Fasting and day long measurement of vascular reactivity in the microcirculation.
Time Frame
Before and after each 8 week intervention.
Title
Change in the total and HDL-cholesterol
Description
Fasting total cholesterol and HDL-C will be measured using a clinical chemistry analyser. LDL-C will be calculated using the Friedewald formula
Time Frame
Before and after each 8 week intervention
Title
Change in fructosamine
Description
Fructosamine will be measured using a clinical chemistry analyser
Time Frame
Before and after each 8 week intervention
Title
Change in C-reactive protein
Description
C-reactive protein
Time Frame
Before and after each 8 week intervention
Title
Change in pulse wave analysis
Description
Pulse wave analysis will be measured using the Mobil-O-Graph device
Time Frame
Before and after each 8 week intervention
Title
Change in blood pressure
Description
Systolic blood pressure, diastolic blood pressure and pulse pressure
Time Frame
Before and after each 8 week intervention
Title
Change in cellular adhesion molecule
Description
VCAM and ICAM will be measured by Luminex, ICAM, P-selectin and E-selectin
Time Frame
Before and after each 8 week intervention
Title
Change in selectins
Description
P-selectin and E-selectin will be measured using Luminex
Time Frame
Before the start of the intervention
Title
Change in beta-hydroxy butyrate
Description
Beta-hydroxy butyrate will be measured using a clinical chemistry analyser as a marker of ketone bodies
Time Frame
Before and after each 8 week intervention
Title
Change in insulin sensitivity
Description
Glucose and insulin levels will be used to estimate insulin sensitivity using the Homeostatic model assessment calculation
Time Frame
Before and after each 8 week intervention
Title
Change in non-esterified fatty acids
Description
Non-esterified fatty acids will be measured using a clinical chemistry analyser
Time Frame
Before and after each 8 week intervention
Title
Measurement of height
Description
Height will be measured using a stadiometer
Time Frame
Before the start of the intervention
Title
Change in body weight
Description
Body weight will be measured using the Tanita scale
Time Frame
Before and after each 8 week intervention
Title
Change in body mass index
Description
Body mass index will be calculated from body weight and height measurement
Time Frame
Before and after each 8 week intervention
Title
Change in body composition
Description
Body composition will be measured using bioelectrical impedance.
Time Frame
Before and after each 8 week intervention
Other Pre-specified Outcome Measures:
Title
Metabonomics
Description
Urinary biomarkers will be measured using NMR
Time Frame
Before and after each 8 week intervention

10. Eligibility

Sex
All
Minimum Age & Unit of Time
20 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: BMI 20-35 kg/m2 HbA1c (5.7 - 6.5%) or (38.8 - 47.5 mmol/mol) Fasting glucose 5.5-6.9 mmol/l Fasting total cholesterol <7.5mmol/l Fasting triacylglycerol <4.0 mmol/l Not having a milk, gluten or wheat allergy or lactose intolerability Not having diabetes (HbA1c < 47 mmol/mol) or < 6.5% Not suffering from cardiovascular, renal, gastrointestinal, respiratory, endocrine or liver disease Not having hypertension Not diagnosed with cancer Not having surgery in the previous 6 months Not consuming more than the recommended intake of alcohol (>14 unit/wk) Not being a blood donor 3 months prior to or during the study. Not taking extra protein powder supplements in the previous 2 months Not anaemic (Haemoglobin ≥115 g/l for women and ≥ 130 g/l for men) Not taking medication for raised blood lipids, high blood pressure or for inflammatory conditions. Exclusion Criteria: • Females who are breast-feeding, may be pregnant, or if of child-bearing potential and are not using effective contraceptive precautions
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Julie Lovegrove, Professor
Phone
0044(0)1183786418
Ext
6418
Email
j.a.lovegrove@reading.ac.uk
First Name & Middle Initial & Last Name or Official Title & Degree
Drew Price, Masters
Phone
00447905106167
Email
a.j.price@pgr.reading.ac.uk
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Julie Lovegrove, Professor
Organizational Affiliation
University of Reading
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hugh Sinclair Unit of Human Nutrition, Department of Food and Nutritional Sciences, University of Reading
City
Reading
State/Province
Berkshire
ZIP/Postal Code
RG6 6AP
Country
United Kingdom
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Julie Lovegrove, Professor
Phone
0044(0)1183786418
Email
j.a.lovegrove@reading.ac.uk
First Name & Middle Initial & Last Name & Degree
Drew Price, Masters
Email
a.j.price@pgr.reading.ac.uk

12. IPD Sharing Statement

Citations:
PubMed Identifier
20377924
Citation
Pal S, Ellis V, Dhaliwal S. Effects of whey protein isolate on body composition, lipids, insulin and glucose in overweight and obese individuals. Br J Nutr. 2010 Sep;104(5):716-23. doi: 10.1017/S0007114510000991. Epub 2010 Apr 9.
Results Reference
background
PubMed Identifier
15531672
Citation
Nilsson M, Stenberg M, Frid AH, Holst JJ, Bjorck IM. Glycemia and insulinemia in healthy subjects after lactose-equivalent meals of milk and other food proteins: the role of plasma amino acids and incretins. Am J Clin Nutr. 2004 Nov;80(5):1246-53. doi: 10.1093/ajcn/80.5.1246.
Results Reference
background

Learn more about this trial

Impact of Whey and Leucine on Glycaemia in Adults Without Diabetes

We'll reach out to this number within 24 hrs